Research
Hormonal
Hypertrophied (enlarged) adipocytes are a significant source of ROS production, primarily via NADPH oxidase (Nox4) and mitochondrial dysfunction, driving local inflammation and metabolic dysfunction.
Large fat cells produce more oxidative stress than small ones. This internal stress contributes to the inflammation and metabolic problems associated with obesity. Reducing fat cell size through weight loss can mitigate this specific source of oxidative stress.
GoodSupportsHIGH confidence
Hypertrophied adipocytes have been reported as a significant source of ROS, promoting WAT dysfunction notably by altering adipokine production [12]. ... NOX4, which does not require other activators and has sustained activity, is the major isoform expressed in adipocytes and is increased in fat cells exposed to excess glucose or palmitate [21].
Why this rating
Supported by multiple studies on adipocyte biology and enzyme expression.
Source
Oxidative Stress and Metabolic Pathologies: From an Adipocentric Point of View
Soazig Le Lay et al. · Oxidative Medicine and Cellular Longevity · 2014
DOI 10.1155/2014/908539
narrative_reviewCited 292×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Chronic elevation of reactive oxygen species (ROS) in adipose tissue causes insulin resistance and metabolic dysfunction by impairing insulin signaling and reducing adiponectin secretion.Good
- Physiological levels of ROS act as beneficial second messengers that promote insulin sensitivity and adipogenesis, whereas chronic elevation leads to insulin resistance.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →